| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0090-4295(97)00292-6 |
| P698 | PubMed publication ID | 9301696 |
| P2093 | author name string | M S Soloway | |
| G Adams | |||
| P F Schellhammer | |||
| H A Murchison | |||
| M Henderson | |||
| J Sheinfeld | |||
| D L Lamm | |||
| M F Sarosdy | |||
| R D Johnson | |||
| G W Chodak | |||
| J V Patel | |||
| M V Jarowenko | |||
| M A Hudson | |||
| B A Blumenstein | |||
| E W Schervish | |||
| K R Thoelke | |||
| R D Pfalzgraf | |||
| R deVere White | |||
| S L Brunelle | |||
| W J Ellis | |||
| P2860 | cites work | Bladder cancer: an overview | Q39604134 |
| Evaluation of bladder washings and urine cytology in the diagnosis of bladder cancer and its correlation with selected biopsies of the bladder mucosa | Q70593545 | ||
| Initial evaluation of the bladder tumor antigen test in superficial bladder cancer | Q70892419 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | bladder cancer | Q504775 |
| P304 | page(s) | 349-353 | |
| P577 | publication date | 1997-09-01 | |
| P1433 | published in | Urology | Q7900884 |
| P1476 | title | Improved detection of recurrent bladder cancer using the Bard BTA stat Test | |
| P478 | volume | 50 |
| Q40612941 | A pilot study of urinary microRNA as a biomarker for urothelial cancer |
| Q35876409 | Alternatives to cytology in the management of non-muscle invasive bladder cancer |
| Q89184326 | An up-to-date catalog of available urinary biomarkers for the surveillance of non-muscle invasive bladder cancer |
| Q73764100 | Analysis of false-positive BTA STAT test results in patients followed up for bladder cancer |
| Q80296315 | Bladder cancer 2000: molecular markers for the diagnosis of transitional cell carcinoma |
| Q77488541 | Bladder tumor markers: need, nature and application. 2. Tumor and tumor-associated antigens |
| Q35190183 | Bladder tumour antigen (BTA stat) test compared to the urine cytology in the diagnosis of bladder cancer: A meta-analysis |
| Q36995765 | Clinical states model for biomarkers in bladder cancer |
| Q40762408 | Comparative evaluation of the BTAstat test, NMP22, and voided urine cytology in the detection of primary and recurrent bladder tumors |
| Q73477491 | Comparison of the monoclonal UBC-ELISA test and the NMP22 ELISA test for the detection of urothelial cell carcinoma of the bladder |
| Q74107590 | Comparison of two qualitative assays, the UBC rapid test and the BTA stat test, in the diagnosis of urothelial cell carcinoma of the bladder |
| Q24654929 | Critical evaluation of urinary markers for bladder cancer detection and monitoring |
| Q57452994 | Current Use and Promise of Urinary Markers for Urothelial Cancer |
| Q34552874 | Detection and diagnosis of blood in feces and urine: an overview |
| Q30985484 | Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine |
| Q46754220 | Diagnosis of urothelial carcinoma |
| Q37507532 | Diagnosis of urothelial carcinoma from urine |
| Q79456680 | Diagnostic Utility of the ImmunoCyt/uCyt+ Test in Bladder Cancer |
| Q64098336 | Effectiveness of bladder tumor antigen quantitative test in the diagnosis of bladder carcinoma in a schistosoma endemic area |
| Q60302268 | Emerging biomarkers for the diagnosis and monitoring of urothelial carcinoma |
| Q33534849 | Evaluation of asymptomatic microscopic hematuria |
| Q46304737 | Exclusion of the uniform tetraploid cells significantly improves specificity of the urine FISH assay |
| Q80608577 | ImmunoCyt/uCyt+ improves the sensitivity of urine cytology in patients followed for urothelial carcinoma |
| Q37827947 | Markers of bladder cancer State of the art. |
| Q73704127 | Mechanistic studies of the effects of anti-factor H antibodies on complement-mediated lysis |
| Q36526271 | Molecular markers in bladder cancer: a critical appraisal |
| Q30636491 | Office evaluation and management of bladder neoplasms |
| Q73261555 | Performance characteristics of multiple urinary tumor markers and sample collection techniques in the detection of transitional cell carcinoma of the bladder |
| Q74419973 | Potential molecular marker for detecting transitional cell carcinoma |
| Q44025949 | ProEx C as an adjunct marker to improve cytological detection of urothelial carcinoma in urinary specimens. |
| Q36623576 | Prognostic utility of human complement factor H related protein test (the BTA stat Test). |
| Q30473183 | Prospective evaluation of the effect of ionizing radiation on the bladder tumor-associated (BTA) urine test |
| Q57825491 | Qualitative and Quantitative Detection of Urinary Human Complement Factor H-Related Protein (BTA stat and BTA TRAK) and Fragments of Cytokeratins 8, 18 (UBC Rapid and UBC IRMA) as Markers for Transitional Cell Carcinoma of the Bladder |
| Q83612735 | Reflex UroVysion testing in suspicious urine cytology cases |
| Q78860659 | Role of uCyt+ in the detection and surveillance of urothelial carcinoma |
| Q34174003 | Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses |
| Q33851139 | Telomerase in human bladder cancer |
| Q74613405 | The BTA stat test: a tumor marker for the detection of upper tract transitional cell carcinoma |
| Q33851127 | The application of human complement factor H-related protein (BTA TRAK) in monitoring patients with bladder cancer |
| Q47721208 | The contemporary role and impact of urine-based biomarkers in bladder cancer |
| Q42721217 | The development of a multitarget, multicolor fluorescence in situ hybridization assay for the detection of urothelial carcinoma in urine |
| Q80461836 | The role of BTA stat Test in follow-up of patients with bladder cancer: results from FinnBladder studies |
| Q73352495 | The role of tumor markers in urologic consultation for screening, diagnosis, and follow-up of bladder cancer |
| Q73676341 | The use of molecular diagnostics in bladder cancer |
| Q43502282 | The value of urinary cytology in the diagnosis of high grade urothelial tumors |
| Q99372492 | Urinary biomarkers in bladder cancer: A review of the current landscape and future directions |
| Q38122367 | Urinary markers for bladder cancer |
| Q33936517 | Urinary markers of malignancy. |
| Q38094284 | Urinary markers/cytology: what and when should a urologist use. |
| Q38140308 | Urine markers for detection and surveillance of bladder cancer |
| Q82480819 | Urine prothymosin-alpha as novel tumor marker for detection and follow-up of bladder cancer |
| Q33643957 | Urine-based assays for the detection of bladder cancer |
| Q73764106 | Usefulness of the BTA STAT Test for the diagnosis of bladder cancer |
| Q35796503 | Value of urinary cytology in the diagnosis and management of urinary tract malignancies |
| Q53377323 | [Non-invasive urinary diagnosis of bladder cancer. What do we know?]. |
| Q79768932 | [Noninvasive and invasive bladder cancer: diagnostics and treatment] |
| Q83353070 | [Tumor marker tests in bladder cancer] |
| Q79990260 | [Value of urinary markers in the diagnosis and follow-up of urothelial bladder tumours] |
| Q82255240 | uCyt+/ImmunoCyt in the detection of recurrent urothelial carcinoma: an update on 1991 analyses |
Search more.